Lapatinib and trastuzumab combination shrinks HER2-positive cancer

被引：0
|
作者：
Coles, Charlotte [1 ]
机构：
[1] Cambridge Univ Hosp NHS Trust, Cambridge, England
来源：
BRITISH JOURNAL OF HOSPITAL MEDICINE | 2016年 / 77卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：206 / 206
页数：1
相关论文
共 50 条
  • [1] Trastuzumab and lapatinib in HER2-positive metastatic colorectal cancer
    Biswas, Bivas
    Rastogi, Sameer
    Batra, Atul
    Ganguly, Sandip
    NATIONAL MEDICAL JOURNAL OF INDIA, 2016, 29 (04): : 219 - 220
  • [2] Lapatinib with trastuzumab for heavily treated HER2-positive metastatic breast cancer (mBC).
    Sotelo, Miguel J.
    Manso, Luis
    Garcia Saenz, Jose Angel
    Ciruelos, Eva M.
    Moreno, Fernando
    Mendiola, Cesar
    Callata, Hector
    Ghanem, Ismael
    Cabezas, Santiago
    Gonzalez-Larriba, Jose-Luis
    Diaz Rubio, Eduardo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Lapatinib in HER2-positive breast cancer
    Nelson, Roxanne
    LANCET ONCOLOGY, 2018, 19 (01): : 22 - 22
  • [4] Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
    Hurvitz, Sara A.
    Kakkar, Reva
    BREAST CANCER-TARGETS AND THERAPY, 2012, 4 : 35 - 51
  • [5] Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC).
    Salvador, Javier
    Ruiz Borrego, Manuel
    Valero, Maria
    Bayo, Juan L.
    De La Cruz-Merino, Luis
    Carabantes, FRancisco
    Rodriguez de la Borbolla, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Safety of the combination of lapatinib (L) plus trastuzumab (T) in patients (pts) with HER2-Positive (+) metastatic breast cancer (MBC)
    Storniolo, A.
    Koehler, M.
    Preston, A.
    Rappold, E.
    Byrne, J.
    Stein, S.
    Ewer, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 187 - 187
  • [7] Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer
    Paridaens, R., Sr.
    Wildiers, H.
    Dalenc, F.
    Rixe, O.
    Cadic, V.
    Pinel, M.
    Roche, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [9] Trastuzumab Rechallenge After Lapatinib- and Trastuzumab-Resistant Disease Progression in HER2-Positive Breast Cancer
    Araki, Kazuhiro
    Fukada, Ippei
    Horii, Rie
    Takahashi, Shunji
    Akiyama, Futoshi
    Iwase, Takuji
    Ito, Yoshinori
    CLINICAL BREAST CANCER, 2015, 15 (06) : 432 - 439
  • [10] Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy
    Blackwell, K. L.
    Burstein, H. J.
    Sledge, G. W.
    Stein, S.
    Ellis, C.
    Casey, M.
    Baselga, J.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2009, 69 (24) : 499S - 499S
12345